Wolfe Research analyst Andy Chen reiterates Celldex Therapeutics (NASDAQ:CLDX) with a Outperform and maintains $51 price target.
Wolfe Research Reiterates Outperform on Celldex Therapeutics, Maintains $51 Price Target
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.